Finalist OF 2024
HerLens
University:
- University of Indonesia
Country:Indonesia
Industries:
- Healthcare Technology,
- FemTech
Supports these SDGs:
)
)
)
)
AI-backed cervical cancer detection
Over 70% of cervical cancer cases in Indonesia are detected at a late stage, largely due to the inaccuracy of existing screening methods like the VIA (Visual Inspection with Acetic Acid) test. While VIA is affordable and widely used in low-resource settings, it relies heavily on visual interpretation by healthcare workers, leading to a high risk of misdiagnosis.
HerLens is addressing this critical health challenge with an innovative solution: a mobile application powered by artificial intelligence (AI) that works alongside a supporting device to help healthcare workers interpret VIA tests with greater accuracy. Designed with simplicity and accessibility in mind, HerLens empowers healthcare workers through an AI-driven solution that enhances the accuracy and reach of cervical cancer screening, addressing a critical need in underserved communities.
)
)
)
Impact
Leveraging insights from over 1,200 VIA test images, HerLens transforms cervical cancer prevention in Indonesia with AI-enhanced VIA tests and advanced pattern recognition for accurate diagnostics. Designed for affordability and accessibility, HerLens empowers healthcare workers by blending technology with clinical expertise, ensuring informed decisions and improving survival through early detection.
24%
reduced treatment expenses
10x
more affordable than alternatives
100
health centers in 25 districts
)
HerLens was built to empower, not replace, healthcare workers. Our goal is to bring accurate, affordable cervical cancer screening to the communities that need it most. With the power of AI and a deep respect for clinical expertise, we’re creating a future where early detection is not a privilege, but a standard.
Andini Putri Pramudya Wardani
Co-founder